Manteio Capital’s Alaunos Therapeutics TCRT Stock Holding History

Manteio Capital’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-699	Closed	-$114K	–	185
2021 Q4	$114K	Buy	+699	New	+$154K	0.15%	214

Other funds holding TCRT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Manteio Capital's TCRT Position: Q1 2022 in Review

Manteio Capital sold out of Alaunos Therapeutics (TCRT) in Q1 2022, closing a stake of 699 shares — an estimated $114K sold.

Manteio Capital first reported a position in TCRT in Q4 2021 and held it in 1 quarter. The position peaked at $114K in Q4 2021. 148 funds tracked by Wall St. Rank hold TCRT as of Q1 2022.

Manteio Capital reported no remaining Alaunos Therapeutics position as of Q1 2022 after selling out during the quarter.
Manteio Capital sold 699 Alaunos Therapeutics shares in Q1 2022, an estimated $114K.
Manteio Capital first reported a position in Alaunos Therapeutics in Q4 2021 and held it in 1 quarter.
Manteio Capital's Alaunos Therapeutics position peaked at $114K in Q4 2021.
148 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q1 2022.

Based on Manteio Capital's 13F filing for Q1 2022.